MotiNRamgopalMDFACP FIDSA
Infectious Disease • Fort Pierce, FLConsultant Physician /Director Associates in Infectious Disease Director/Founder Midway Immunology and Research Center Asst.Professor Medicine Florida State University Medical School
Dr. Ramgopal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
356 E Midway Rd
Fort Pierce, FL 34982Phone+1 772-464-9746Fax+1 772-464-9750
Summary
- Dr. Moti Ramgopal is an infectious disease specialist in Fort Pierce, FL and is affiliated with multiple hospitals in the area, including Lawnwood Regional Medical Center & Heart Institute, Port St. Lucie Hospital, and St. Lucie Medical Center. He received his medical degree from University of the West Indies Faculty of Medical Sciences and has been in practice 28 years. He is experienced in travel and tropical medicine, infectious disease, osteomyelitis, prevertebral infection, and mandibular space infection.
Education & Training
University of Miami/Jackson Health SystemFellowship, Infectious Disease, 1995 - 1997
Bon Secours HospitalResidency, Internal Medicine, 1992 - 1995
University of the West Indies Faculty of Medical SciencesClass of 1989
Certifications & Licensure
FL State Medical License 1996 - 2026
MI State Medical License 1994 - 1998- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV Start of enrollment: 2015 Aug 01
Publications & Presentations
PubMed
- 5 citationsSafety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study.Joseph J Eron, Susan J Little, Gordon Crofoot, Paul Cook, Peter J Ruane
The Lancet. HIV. 2024-03-01 - 914 citationsThe major genetic determinants of HIV-1 control affect HLA class I peptide presentationFlorencia Pereyra, Xiaoming Jia, Paul J. McLaren, Amalio Telenti, de Bakker Pi
Science. 2010-12-10 - 13 citationsProactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophyla...Michelle Cespedes, Moupali Das, J Carlo Hojilla, Jill Blumenthal, Karam Mounzer
Plos One. 2022-01-01
Press Mentions
COVID Surge: What if We Had Just Listened to Local Doctors Pierone, Ramgopal? | OpinionAugust 6th, 2021- The Science of COVID-19: COVID-19 and Treatment of AdultsMarch 8th, 2021
- Doctor Says We Need to Be One Step Ahead of the VariantFebruary 16th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
